Armodafinil promotes wakefulness and activates Fos in rat brain

详细信息    查看全文

• 作者：Elaine M. Fiocchi ; Yin-Guo Lin ; Lisa Aimone ; John A. Gruner ; Dorothy G. Flood
• 关键词：Sleep ; Waking ; Narcolepsy ; Fos ; Immediate early gene ; Immunohistochemistry ; Armodafinil ; Rat
• 刊名：Pharmacology Biochemistry and Behavior
• 出版年：2009
• 出版时间：May 2009
• 年：2009
• 卷：92
• 期：3
• 页码：549-557
• 全文大小：618 K

文摘

Modafinil increases waking and labeling of Fos, a marker of neuronal activation. In the present study, armodafinil, the R-enantiomer of racemic modafinil, was administered to rats at 30 or 100 mg/kg i.p. about 5 h after lights on (circadian time 5 and near the midpoint of the sleep phase of the sleep:wake cycle) to assess its effects on sleep/wake activity and Fos activation. Armodafinil at 100 mg/kg increased wakefulness for 2 h, while 30 mg/kg armodafinil only briefly increased wakefulness. Armodafinil (30 and 100 mg/kg) also increased latencies to the onset of sleep and motor activity. Armodafinil had differential effects in increasing neuronal Fos immunolabeling 2 h after administration. Armodafinil at 100 mg/kg increased numbers of Fos-labeled neurons in striatum and anterior cingulate cortex, without affecting nucleus accumbens. Armodafinil at 30 mg/kg only increased numbers of light Fos-labeled neurons in the anterior cingulate cortex. In brainstem arousal centers, 100 mg/kg armodafinil increased numbers of Fos-labeled neurons in the tuberomammillary nucleus, pedunculopontine tegmentum, laterodorsal tegmentum, locus coeruleus, and dorsal raphe nucleus. Fos activation of these brainstem arousal centers, as well as of the cortex and striatum, is consistent with the observed arousal effects of armodafinil.